Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a randomized controlled trial. Academic Article uri icon

Overview

abstract

  • BACKGROUND: New antibacterial agents with activity against pathogenic strains resistant to established antibiotics are needed to treat patients with secondarily infected dermatitis (SID). OBJECTIVE: We sought to determine the clinical safety and efficacy of topical retapamulin ointment 1% versus oral cephalexin for the treatment of SID. METHODS: Patients with SID were randomly assigned to retapamulin ointment 1% (twice daily [bid]) for 5 days, or oral cephalexin (500 mg bid) for 10 days. The primary efficacy end point was clinical response at follow-up. Secondary outcomes included microbiologic response at follow-up, safety, and compliance. RESULTS: Retapamulin was as effective as cephalexin (clinical success rates at follow-up: 85.9% and 89.7%, respectively). Microbiologic success rates at follow-up were 87.2% for retapamulin and 91.8% for cephalexin. Retapamulin was well tolerated and the topical formulation was preferred over the oral drug. LIMITATIONS: An imbalance existed in the number of patients with the clinical outcome "unable to determine" (15 retapamulin, 2 cephalexin), mainly because of their failure to attend the study visit. If those who failed to attend visits (who did not withdraw as a result of drug-related events) are removed from the analysis, the clinical success rates are 89.9% for retapamulin and 89.7% for cephalexin. CONCLUSIONS: Retapamulin ointment 1% (bid) for 5 days was as effective as oral cephalexin (bid) for 10 days in treatment of patients with SID, and was well tolerated.

publication date

  • October 6, 2006

Research

keywords

  • Anti-Bacterial Agents
  • Bridged Bicyclo Compounds, Heterocyclic
  • Cephalexin
  • Dermatitis
  • Skin Diseases, Infectious
  • Staphylococcal Skin Infections
  • Streptococcal Infections
  • Streptococcus pyogenes

Identity

Scopus Document Identifier

  • 33750801913

Digital Object Identifier (DOI)

  • 10.1016/j.jaad.2006.08.058

PubMed ID

  • 17097398

Additional Document Info

volume

  • 55

issue

  • 6